Search

Your search keyword '"Conconi, Annarita"' showing total 14 results
Start Over Author "Conconi, Annarita" Publication Year Range Last 3 years
14 results on '"Conconi, Annarita"'

1. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Published
2024
Full Text
View/download PDF

2. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma

Author

Conconi, Annarita, Chiappella, Annalisa, Ferreri, Andrés J. M., Stathis, Anastasios, Botto, Barbara, Sassone, Marianna, Gaidano, Gianluca, Balzarotti, Monica, Merli, Francesco, Tucci, Alessandra, Vanazzi, Anna, Tani, Monica, Bruna, Riccardo, Orsucci, Lorella, Cabras, Maria Giuseppina, Celli, Melania, Annibali, Ombretta, Liberati, Anna Marina, Zanni, Manuela, Ghiggi, Chiara, Pisani, Francesco, Pinotti, Graziella, Dore, Fausto, Esposito, Fabiana, Pirosa, Maria Cristina, Cesaretti, Marina, Bonomini, Luisella, Vitolo, Umberto, and Zucca, Emanuele

Published
2024
Full Text
View/download PDF

4. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Author

Visco, Carlo, Marcheselli, Luigi, Mina, Roberto, Sassone, Marianna, Guidetti, Anna, Penna, Domenico, Cattaneo, Chiara, Bonuomo, Valentina, Busca, Alessandro, Ferreri, Andrés José María, Bruna, Riccardo, Petrucci, Luigi, Cairoli, Roberto, Salvini, Marco, Bertù, Lorenza, Ladetto, Marco, Pilerci, Sofia, Pinto, Antonello, Ramadan, Safaa, Marchesi, Francesco, Cavo, Michele, Arcaini, Luca, Coviello, Elisa, Romano, Alessandra, Musto, Pellegrino, Massaia, Massimo, Fracchiolla, Nicola, Marchetti, Monia, Scattolin, Annamaria, Tisi, Maria Chiara, Cuneo, Antonio, Della Porta, Matteo, Trentin, Livio, Turrini, Marco, Gherlinzoni, Filippo, Tafuri, Agostino, Galimberti, Sara, Bocchia, Monica, Cardinali, Valeria, Cilloni, Daniela, Corso, Alessandro, Armiento, Daniele, Rigacci, Luigi, La Barbera, Elettra Ortu, Gambacorti-Passerini, Carlo, Visani, Giuseppe, Vallisa, Daniele, Venditti, Adriano, Selleri, Carmine, Conconi, Annarita, Tosi, Patrizia, Lanza, Francesco, Candoni, Anna, Krampera, Mauro, Corradini, Paolo, Passamonti, Francesco, and Merli, Francesco

Published
2022
Full Text
View/download PDF

5. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

Author

Stathis, Anastasios, primary, Pirosa, Maria Cristina, additional, Orsucci, Lorella, additional, Feugier, Pierre, additional, Tani, Monica, additional, Ghesquières, Hervé, additional, Musuraca, Gerardo, additional, Rossi, Francesca Gaia, additional, Merli, Francesco, additional, Guièze, Romain, additional, Gyan, Emmanuel, additional, Gini, Guido, additional, Marino, Dario, additional, Gressin, Remy, additional, Morschhauser, Franck, additional, Cavallo, Federica, additional, Palombi, Francesca, additional, Conconi, Annarita, additional, Tessoulin, Benoît, additional, Tilly, Hervé, additional, Zanni, Manuela, additional, Cabras, Maria Giuseppina, additional, Capochiani, Enrico, additional, Califano, Catello, additional, Celli, Melania, additional, Pulsoni, Alessandro, additional, Angrilli, Francesco, additional, Occhini, Ubaldo, additional, Casasnovas, René-Olivier, additional, Cartron, Guillaume, additional, Devizzi, Liliana, additional, Haioun, Corinne, additional, Liberati, Anna Marina, additional, Houot, Roch, additional, Merli, Michele, additional, Pietrantuono, Giuseppe, additional, Re, Francesca, additional, Spina, Michele, additional, Landi, Francesco, additional, Cavalli, Franco, additional, Bertoni, Francesco, additional, Rossi, Davide, additional, Ielmini, Nicoletta, additional, Borgo, Elena, additional, Luminari, Stefano, additional, Zucca, Emanuele, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

6. Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi

Author

Nizzoli, Maria E., primary, Manni, Martina, additional, Ghiggi, Chiara, additional, Pulsoni, Alessandro, additional, Musuraca, Gerardo, additional, Merli, Michele, additional, Califano, Catello, additional, Bari, Alessia, additional, Massaia, Massimo, additional, Conconi, Annarita, additional, Musto, Pellegrino, additional, Mannina, Donato, additional, Perrone, Tommasina, additional, Re, Francesca, additional, Galimberti, Sara, additional, Gini, Guido, additional, Capponi, Monia, additional, Vitolo, Umberto, additional, Usai, Sara V., additional, Stefani, Piero M., additional, Ballerini, Filippo, additional, Liberati, Anna M., additional, Pennese, Elsa, additional, Pastore, Domenico, additional, Skrypets, Tetiana, additional, Catellani, Hillary, additional, Marcheselli, Luigi, additional, Federico, Massimo, additional, and Luminari, Stefano, additional

Published
2023
Full Text
View/download PDF

8. Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., additional, Habermann, Thomas M., additional, Link, Brian K., additional, Thieblemont, Catherine, additional, Conconi, Annarita, additional, Larson, Melissa C., additional, Cascione, Luciano, additional, Zhao, Wei, additional, Cerhan, James R., additional, Zucca, Emanuele, additional, and Lossos, Izidore S., additional

Published
2022
Full Text
View/download PDF

9. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma

Author

Alderuccio, Juan Pablo, Reis, Isildinha M, Habermann, Thomas M, Link, Brian K, Thieblemont, Catherine, Conconi, Annarita, Larson, Melissa C, Cascione, Luciano, Zhao, Wei, Cerhan, James R, Zucca, Emanuele, and Lossos, Izidore S

Subjects
610 Medizin und Gesundheit
Abstract

Extranodal marginal zone lymphoma (EMZL) is a heterogeneous disease with a subset of patients exhibiting a more aggressive course. We previously reported that EMZL with multiple mucosal sites (MMS) at diagnosis is characterized by shorter survival. To better recognize patients with different patterns of progression-free survival (PFS) we developed and validated a new prognostic index primarily based on patient's disease characteristics. We derived the "Revised mucosa-associated lymphoid tissue International Prognostic Index" (Revised MALT-IPI) in a large data set (n=397) by identifying candidate variables that showed highest prognostic association with PFS. The revised MALT-IPI was validated in two independent cohorts, from the University of Iowa/Mayo Clinic (n=297) and from IELSG-19 study (n=400). A stepwise Cox regression analysis yielded a model including four independent predictors of shorter PFS. Revised MALT-IPI has scores ranging from 0 to 5, calculated as a sum of 1 point for each of the following- age >60 years, elevated LDH, and stage III-IV; and 2 points for MMS. In the training cohort, the Revised MALT-IPI defined 4 risk groups: low risk (score 0, reference group), low-medium risk (score 1, HR=1.85, P=0.008), medium-high risk (score 2, HR=3.84, P

Published
2022
Full Text
View/download PDF

10. Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

Author

Benevolo, Giulia, primary, Ferrero, Simone, additional, Villivà, Nicoletta, additional, Castiglione, Anna, additional, Monaco, Federico, additional, Boccomini, Carola, additional, Cabras, Maria Giuseppina, additional, Califano, Catello, additional, Casula, Paolo, additional, Cavallo, Federica, additional, Conconi, Annarita, additional, Drandi, Daniela, additional, Gaidano, Gianluca, additional, Gregorini, Anna Ines, additional, Felici, Stefano, additional, Ferrante, Martina, additional, Mannina, Donato, additional, Molinari, Anna Lia, additional, Musto, Pellegrino, additional, Musuraca, Gerardo, additional, Merli, Michele, additional, Sartori, Roberto, additional, Tani, Monica, additional, Varettoni, Marzia, additional, Vitolo, Umberto, additional, and Orsucci, Lorella, additional

Published
2021
Full Text
View/download PDF

11. Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Author

Luminari, Stefano, primary, Nizzoli, Maria Elena, additional, Chiarenza, Annalisa, additional, Mannina, Donato, additional, Tucci, Alessandra, additional, Boccomini, Carola, additional, Farina, Lucia, additional, Olivieri, Jacopo, additional, Marcheselli, Luigi, additional, Ferrero, Simone, additional, Arcaini, Luca, additional, Pulsoni, Alessandro, additional, Musuraca, Gerardo, additional, Califano, Catello, additional, Merli, Michele, additional, Bari, Alessia, additional, Conconi, Annarita, additional, Re, Francesca, additional, Balzarotti, Monica, additional, Ladetto, Marco, additional, Patti, Caterina, additional, Pinto, Antonello, additional, Cabras, Maria Giuseppina, additional, Musto, Pellegrino, additional, Gini, Guido, additional, Arcari, Annalisa, additional, Manni, Martina, additional, Versari, Annibale, additional, and Federico, Massimo, additional

Published
2021
Full Text
View/download PDF

12. Rituximab and Lenalidomide (R 2) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Author

Boccomini, Carola, Botto, Barbara, Evangelista, Andrea, Zilioli, Vittorio Ruggero, Anastasia, Antonella, Cavallo, Federica, Merli, Francesco, Zanni, Manuela, Tani, Monica, Chiarenza, Annalisa, Liberati, Anna Marina, Conconi, Annarita, Corradini, Paolo, Bari, Alessia, Annechini, Giorgia, Gaidano, Gianluca, Spina, Michele, Sartori, Roberto, Castellino, Claudia, Puccini, Benedetta, Arcari, Annalisa, Bigliardi, Sara, Matta, Giorgia, Merli, Michele, Mannina, Donato, Marino, Dario, Galieni, Piero, Ciambelli, Fabrizio, Musuraca, Gerardo, Bottelli, Chiara, Muzi, Cristina, Ferrero, Simone, Luminari, Stefano, Ladetto, Marco, Ciccone, Giovannino, and Vitolo, Umberto

Abstract

Background:Elderly patients with relapsed/refractory (R/R) FL have limited treatment options. Lenalidomide has direct tumoricidal and antiangiogenetic actions on tumor cells and is able to modulate tumor-cell microenvironment. Lenalidomide combined with Rituximab (R 2) in induction has shown a good clinical activity with low toxicity in both untreated and R/R FL patients. R 2as maintenance treatment is less studied.

Published
2023
Full Text
View/download PDF

13. Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL)

Author

Thieblemont, Catherine, Conconi, Annarita, Buske, Christian, Luminari, Stefano, Dreyling, Martin, da Silva, Maria Gomes, Andre, Marc, Flores, Maria, Brahami-Aissou, Karima, Cony-Makhoul, Pascale, and Carras, Sylvain

Abstract

Background

Published
2023
Full Text
View/download PDF

14. Early complete response a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

Author

Bommier, Côme, Zucca, Emanuele, Chevret, Sylvie, Conconi, Annarita, Nowakowski, Grzegorz, Maurer, Matthew J., Cerhan, James R., Thieblemont, Catherine, and Lambert, Jérôme

Abstract

•Surrogate markers provide early decision-making end points for regulatory agencies; they serve as substitutes for long-term end points.•In extranodal MZL, CR24 mediates 90% and TTCR24 captures 95% of treatment effect on 8-year PFS, which makes them valid early indicators.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results